The mean changes from baseline to week 26 were -3.8 kg and -3.7 kg in the RYBELSUS 14 mg and empagliflozin 25 mg arms, respectively
Before you place the order Double-check the version, quantity, included details, and delivery timing so the final choice lines up with what you actually need
Given the frequent coexistence of obesity and T2D with cardiovascular disease and chronic kidney disease (CKD), incretin-based therapies (encompassing selective GLP-1 and multi-receptor agonists) have emerged as disease-modifying treatments across the cardiovascularkidneymetabolic (CKM) spectrum
Kushner, M.D., Ildiko Lingvay, M.D., M.P.H., Tugce K
The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time